Daidzein and 17 beta-estradiol enhance nitric oxide synthase activity associated with an increase in calmodulin and a decrease in caveolin-1

J Cardiovasc Pharmacol. 2004 Aug;44(2):155-63. doi: 10.1097/00005344-200408000-00003.

Abstract

Isoflavones, such as daidzein, are proposed to possess vasculoprotective properties, perhaps through a mechanism similar to estrogen. Our experiments aimed to test the hypothesis that daidzein and 17 beta-estradiol enhance endothelium-dependent relaxation through an increase in NO synthesis due to an increase in activity or expression of endothelial nitric oxide synthase (eNOS). Male rats were treated with daidzein (0.2 mg/kg per day sc), 17 beta-estradiol (0.1 mg/kg per day sc), or vehicle for 7 days and reactivity of isolated aortic rings was then determined. ACh-induced relaxation was significantly enhanced in aortic rings from rats treated with daidzein or 17 beta-estradiol but the relaxant responses to the endothelium-independent dilators sodium nitroprusside or isoprenaline were not different. Nitrite production and the level of cGMP were significantly greater in aortae from daidzein and 17 beta-estradiol compared with vehicle-treated rats. Daidzein and 17 beta-estradiol did not alter eNOS protein in endothelium-intact aortae but reduced expression of caveolin-1 and increased expression of calmodulin, changes that would account for an increase in eNOS activity. There were no differences between groups in the expression of calmodulin and caveolin-1 in arteries when the endothelium was removed. Daidzein or 17 beta-estradiol treatment selectively enhances endothelium-dependent relaxation in male rats through an increase in eNOS activity. The increase in eNOS activity is associated with a decreased expression of caveolin-1 and an increased expression of calmodulin in endothelial cells.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Animals
  • Aorta / cytology
  • Aorta / drug effects
  • Aorta / metabolism
  • Body Weight / drug effects
  • Calmodulin / genetics
  • Calmodulin / metabolism*
  • Caveolin 1
  • Caveolins / antagonists & inhibitors
  • Caveolins / genetics
  • Caveolins / metabolism*
  • Cyclic GMP / chemistry
  • Cyclic GMP / metabolism
  • Drug Synergism
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / pathology
  • Estradiol / administration & dosage
  • Estradiol / analogs & derivatives*
  • Estradiol / pharmacokinetics*
  • Estradiol / pharmacology
  • Fulvestrant
  • Gene Expression / drug effects
  • Gene Expression / physiology
  • Injections, Subcutaneous
  • Isoflavones / administration & dosage
  • Isoflavones / pharmacokinetics*
  • Isoproterenol / pharmacology
  • Male
  • Muscle Contraction / drug effects
  • Muscle Relaxation / drug effects
  • Muscle, Smooth, Vascular / drug effects
  • Nitric Oxide / biosynthesis
  • Nitric Oxide / genetics
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase / chemistry
  • Nitric Oxide Synthase / genetics
  • Nitric Oxide Synthase / metabolism*
  • Nitric Oxide Synthase Type III
  • Nitroarginine / pharmacology
  • Nitroprusside / pharmacology
  • Organ Size / drug effects
  • Phenoxybenzamine / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Testis / anatomy & histology
  • Testis / drug effects

Substances

  • Calmodulin
  • Cav1 protein, rat
  • Caveolin 1
  • Caveolins
  • Isoflavones
  • Phenoxybenzamine
  • Nitroprusside
  • Nitroarginine
  • Fulvestrant
  • Nitric Oxide
  • Estradiol
  • daidzein
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type III
  • Nos3 protein, rat
  • Cyclic GMP
  • Isoproterenol
  • Acetylcholine